Regulus Therapeutics Inc. (RGLS) was among the biggest gainers on the Russell 2000 for Wednesday December 23 as the stock popped 5.25% to $9.83, representing a gain of $0.49 per share. Some 316,168 shares traded hands on 2,369 trades, compared with an average daily volume of 591,243 shares out of a total float of 52.34 million. The stock opened at $9.42 and traded with an intraday range of $10.00 to $9.31.
After today's gains, Regulus Therapeutics Inc. reached a market cap of $514.53 million. Regulus Therapeutics Inc. has had a trading range between $21.22 and $5.85 over the last year, and it had a 50-day SMA of $8.51 and a 200-day SMA of $10.72.
Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering and developing drugs that target micro RNAs to treat various diseases.
Regulus Therapeutics Inc. is based out of San Diego, CA and has some 82 employees. Its CEO is Paul Grint.
For a complete fundamental analysis analysis of Regulus Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for RGLS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.